申请人:SUMITOMO PHARMACEUTICALS COMPANY, LIMITED
公开号:EP0947515A1
公开(公告)日:1999-10-06
Naphthyridine derivative of the formula:
wherein Ring A is substituted or unsubstituted pyridine ring, X is ―N(R2)―CO― (R2 is H, alkyl, substituted alkyl, etc.), Z is a direct bond, ―NH―, C1-2 alkylene, or ―CH=CH―, Y is aromatic group or substituted aromatic group, L is alkyl, substituted alkyl, aromatic group or substituted aromatic group, or an acid addition salt thereof, these compounds exhibiting acyl-CoA: cholesterol acyl transferase inhibitory activity, and being useful as an agent for prophylaxis or treatment of hyperlipidemia, atherosclerosis, and related diseases thereof.
式中的萘啶衍生物:
其中环 A 是取代或未取代的吡啶环,X 是-N(R2)-CO-(R2 是 H、烷基、取代烷基等),Z 是直接键、-NH-、C1-2 亚烷基或-CH=CH-,Y 是芳香基团或取代芳香基团,L 是烷基、C1-2 亚烷基或-CH=CH-。Z为直接键、-NH-、C1-2亚烷基或-CH=CH-,Y为芳香基团或取代的芳香基团,L为烷基、取代的烷基、芳香基团或取代的芳香基团,或其酸加成盐,这些化合物具有酰基-CoA:胆固醇酰基转移酶抑制活性,可作为预防或治疗高脂血症、动脉粥样硬化及其相关疾病的药物。